Journal
STROKE
Volume 39, Issue 10, Pages 2891-2893Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.107.505875
Keywords
vasospasm; delayed cerebral ischemia; clinical trial
Categories
Funding
- National Institutes of Health NCRR [K30-RR022292-07]
Ask authors/readers for more resources
Background and Purpose - Studies suggest statins ameliorate aneurysmal subarachnoid hemorrhage (SAH)-induced cerebral vasospasm and ischemic complications. We tested safety and feasibility of simvastatin 80 mg/d for vasospasm prevention in SAH patients. Methods - Thirty-nine statin-naive Fisher grade 3 SAH subjects were double-blind randomized to receive simvastatin 80 mg/d (n = 19) or placebo (n = 20), stratified by Hunt and Hess grade. Primary end points were death and drug morbidity. Results - Mortality was 3/20 in the placebo and 0/19 in the simvastatin group. Study drug was withdrawn in 1 subject in each treatment group for reversible liver enzyme or creatine phosphokinase elevation. Angiographically-confirmed vasospasm occurred in 8/20 placebo and 5/19 simvastatin-treated subjects. Vasospasm-related ischemic infarcts developed in 5/20 placebo and 2/19 simvastatin-treated subjects. Conclusion - Simvastatin for the prevention of delayed cerebral ischemia is safe and feasible after SAH. A larger study is needed to test its efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available